Loading Pathway...
Error: Pathway image not found.
Hide
Pathway Description
Clobetasone Action Pathway
Homo sapiens
Drug Action Pathway
Clobetasone is a corticosteroid synthetically derived from cortisone. In dermatology, topical clobestasone helps to reduce the itchiness and erythema associated with eczema and dermatitis. In ophthalmology, clobetasone butyrate eye drops have been shown to be safe and effective in the treatment of dry eyes in Sjögren's Syndrome. As this drug is a glucocorticoid, its mechanism of action is that of the glucocorticoid response element (GRE) influencing COX-2/prostaglandin G/H synthase 2 suppression and lipocortin/annexin induction. By binding to the glucocorticoid receptor, it influences transcription factors AP-1 and NF-kB to block the transcription of COX-2/prostaglandin G/H synthase 2 which reduces the amount of prostanoids being produced from arachidonic acid. Prostanoids such as PGI2 and thromboxane A2 influence the effects of inflammation through vasoconstriction/dilation, pain sensitivity, and platelet aggregation. Clobetasone also affects the promoter of annexin-1, an important inflammatory protein as it affects leukocytes and blocks phospholipase A2 which reduces the amount of arachidonic acid being cleaved from the phospholipid bilayer. Reducing the amount of arachidonic acid formed further decreases the concentrations of prostanoids mentioned calming inflammation.
References
Clobetasone Pathway References
Wishart DS, Feunang YD, Guo AC, Lo EJ, Marcu A, Grant JR, Sajed T, Johnson D, Li C, Sayeeda Z, Assempour N, Iynkkaran I, Liu Y, Maciejewski A, Gale N, Wilson A, Chin L, Cummings R, Le D, Pon A, Knox C, Wilson M: DrugBank 5.0: a major update to the DrugBank database for 2018. Nucleic Acids Res. 2018 Jan 4;46(D1):D1074-D1082. doi: 10.1093/nar/gkx1037.
Pubmed: 29126136
Munro DD, Wilson L: Clobetasone butyrate, a new topical corticosteroid: clinical activity and effects on pituitary-adrenal axis function and model of epidermal atrophy. Br Med J. 1975 Sep 13;3(5984):626-8. doi: 10.1136/bmj.3.5984.626.
Pubmed: 1164639
Goustas P, Cork MJ, Higson D: Eumovate (clobetasone butyrate 0.05%) cream: a review of clinical efficacy and safety. J Dermatolog Treat. 2003 Jun;14(2):71-85. doi: 10.1080/09546630310004180.
Pubmed: 12775314
Kim S, Ko J, Kim JH, Choi EC, Na DS: Differential effects of annexins I, II, III, and V on cytosolic phospholipase A2 activity: specific interaction model. FEBS Lett. 2001 Feb 2;489(2-3):243-8. doi: 10.1016/s0014-5793(00)02326-7.
Pubmed: 11165258
Necela BM, Cidlowski JA: Mechanisms of glucocorticoid receptor action in noninflammatory and inflammatory cells. Proc Am Thorac Soc. 2004;1(3):239-46. doi: 10.1513/pats.200402-005MS.
Pubmed: 16113441
Perretti M, Dalli J: Exploiting the Annexin A1 pathway for the development of novel anti-inflammatory therapeutics. Br J Pharmacol. 2009 Oct;158(4):936-46. doi: 10.1111/j.1476-5381.2009.00483.x.
Pubmed: 19845684
Oeckinghaus A, Ghosh S: The NF-kappaB family of transcription factors and its regulation. Cold Spring Harb Perspect Biol. 2009 Oct;1(4):a000034. doi: 10.1101/cshperspect.a000034.
Pubmed: 20066092
Kang YJ, Mbonye UR, DeLong CJ, Wada M, Smith WL: Regulation of intracellular cyclooxygenase levels by gene transcription and protein degradation. Prog Lipid Res. 2007 Mar;46(2):108-25. doi: 10.1016/j.plipres.2007.01.001. Epub 2007 Jan 18.
Pubmed: 17316818
Kirschke E, Goswami D, Southworth D, Griffin PR, Agard DA: Glucocorticoid receptor function regulated by coordinated action of the Hsp90 and Hsp70 chaperone cycles. Cell. 2014 Jun 19;157(7):1685-97. doi: 10.1016/j.cell.2014.04.038.
Pubmed: 24949977
Highlighted elements will appear in red.
Highlight Compounds
Highlight Proteins
Enter relative concentration values (without units). Elements will be highlighted in a color gradient where red = lowest concentration and green = highest concentration. For the best results, view the pathway in Black and White.
Visualize Compound Data
Visualize Protein Data
Downloads
Settings